Neoadjuvant FOLFOX Chemotherapy for Colon Cancer: Long-Term Chemotherapy-Induced Peripheral Neuropathy and Impact on Quality of Life

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

54 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-19

Study Completion Date

2024-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study was to learn about the long-term effects of neoadjuvant (pre-surgery) chemotherapy on patients with locally advanced colon cancer. The main focus was to better understand the severity of long-lasting nerve damage, known as chemotherapy-induced peripheral neuropathy (CIPN), and its impact on patients' quality of life (QoL).

The key question the study aimed to answer was: What is the long-term severity of this common adverse event, and how much of an impact does it have on patients' quality of life?

Participants provided detailed responses about the severity of their CIPN symptoms and the overall impact on their well-being using the FACT-GOG-Ntx questionnaire.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

NCT03426904

Colon Cancer

ACTIVE_NOT_RECRUITING PHASE3

Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer

NCT03484195

Colonic Neoplasms Drug Therapy

UNKNOWN PHASE2

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

NCT04164069

Advanced Colorectal Carcinoma Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 +13 more

COMPLETED PHASE1

MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer

NCT06890624

Colon Cancer (stage II &amp; III)

NOT_YET_RECRUITING PHASE2

Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

NCT05378919

Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect experienced by many cancer patients receiving neurotoxic agents such as oxaliplatin. CIPN can manifest as numbness, tingling, and neuropathic pain, significantly impairing patients' quality of life (QoL). While the acute development of CIPN during chemotherapy treatment is well documented, the long-term persistence and severity of CIPN symptoms after completion of therapy is less understood.

The relatively new approach to treatment of patients with locally advanced colon cancer involves starting treatment with neoadjuvant (pre-operative) chemotherapy regimens containing oxaliplatin, such as FOLFOX, followed by definitive surgical resection and potentially additional adjuvant chemotherapy. This strategy has proven to be non-inferior to more established adjuvant (post-operative) chemotherapy, according to results of several clinical trials. However, the impact of this long-term CIPN on patient-reported outcomes and QoL in the setting of neoadjuvant chemotherapy has not been thoroughly investigated.

Additionally, there is interest in exploring whether modifying the sequence of neoadjuvant and adjuvant chemotherapy regimens could potentially mitigate the severity of CIPN. Specifically, a hypothesis can be made that delivering a reduced volume of oxaliplatin-containing chemotherapy (6 cycles of neoadjuvant FOLFOX) followed by a break for surgery, with only selective use of additional adjuvant chemotherapy based on response, may result in less cumulative neurotoxicity and improved long-term CIPN outcomes compared to the standard approach of administering the full course of chemotherapy after surgery.

The primary objective of this observational study was to characterize the long-term severity of CIPN symptoms and the associated impact on QoL in patients with locally advanced colon cancer who received neoadjuvant FOLFOX chemotherapy, followed by surgical resection and response-dependent adjuvant chemotherapy.

Study Design and Participants. This was a single-center, prospective observational study conducted at an academic medical center. Adult patients (≥18 years old) with histologically confirmed, locally advanced adenocarcinoma of the colon (clinical stage III or high-risk stage II) were eligible for enrollment. Key inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, adequate organ function, and no prior systemic chemotherapy or radiotherapy.

Eligible patients were enrolled and received 6 cycles of neoadjuvant FOLFOX chemotherapy. FOLFOX consisted of oxaliplatin 85 mg/m2 IV on day 1, leucovorin 400 mg/m2 IV on day 1, and 5-fluorouracil 400 mg/m2 IV bolus on day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours, every 2 weeks.

After completing six cycles of neoadjuvant FOLFOX chemotherapy, patients underwent definitive surgical resection of their primary tumor. For those who achieved a favorable pathologic response (defined as pT0-2N0M0 or pT3N0M0 without risk factors), no additional adjuvant chemotherapy was administered post-surgery. However, in cases of pT3N0M0 with the presence of risk factors, patients received 3 months of adjuvant capecitabine. Patients with a poor pathologic response were offered an additional six cycles of adjuvant FOLFOX chemotherapy.

Assessment of CIPN. Throughout the course of treatment, patients underwent clinical assessments for the development of CIPN. During treatment, a physician performed a neurological examination and graded the severity of CIPN using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. This standardized grading system classifies CIPN from grade 1 (mild) to grade 4 (life-threatening).

At a minimum of 3 months after the end of platinum-containing chemotherapy treatment, patients completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx) questionnaire. The FACT-GOG-Ntx is a validated, patient-reported outcome measure that evaluates the severity of CIPN symptoms and their impact on daily functioning and QoL.

The primary endpoint of this observational study was assessment of the long-term severity of CIPN and its impact on QoL, as measured by the FACT-GOG-Ntx questionnaire. The secondary target was assessment of correlation between various risk factors (older age (\> 65 years), diabetes, Eastern Cooperative Oncology Group (ECOG) performance status, Body mass index (BMI) \> 25, and higher cumulative oxaliplatin dose; cold temperatures during treatment) and severity of long-term CIPN.

Statistical Considerations. Descriptive statistics were used to summarize characteristics of patients. Associations between risk factors and ACIPN severity were evaluated using chi-squared tests. Two-tailed Mann-Whitney U tests were used to show significant differences in long-term CIPN outcomes and QoL scores between patient groups. Pearson and Spearman correlations were used to evaluate associations between risk factors and CIPN severity. Statistical significance was set at p \< 0.05. Statistical analyses were performed using JASP (Version 0.18.3), an open-source statistical software package (JASP Team, 2024) or GraphPad Prism (GraphPad Software, San Diego, CA, USA).

Results. Between March 2021 and February 2024, a total of 54 patients were included and assessed by clinicians for acute CIPN during treatment. 45 of these patients provided complete FACT-GOG-Ntx questionnaire data for the long-term CIPN assessment, and 40 were included in the QoL analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with colon cancer (II-III stage) who received neoadjuvant FOLFOX chemotherapy

54 Patients with locally advanced colon cancer who received platinum-containing chemotherapy as the initial phase of their treatment, followed by surgical resection and, if indicated, adjuvant chemotherapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with newly diagnosed, histologically confirmed, resectable colon cancer stage IIA - IIIC (cT3N0M0 \[depth of invasion \> 5 mm\], cT4a-T4bN0M0, T1-4N1-2M0).
* Age \< 75 years.
* ECOG performance status 0-1.
* Hemoglobin \> 9 g/dL.
* Absolute neutrophil count \> 1500/µL.
* Platelet count \> 100,000/µL.
* Bilirubin level \< 1.5 times the upper limit of normal.
* Creatinine clearance \> 60 mL/min (calculated using the Cockcroft-Gault formula).
* ALT and AST levels \< 2.5 times the upper limit of normal.

Exclusion Criteria

* Presence of distant metastases.
* History of other oncological diseases, except for:

1. Cured non-melanoma skin cancer without known signs of recurrence or progression for \> 5 years.
2. Cured carcinoma in situ without signs of recurrence or progression for \> 5 years.
* Clinically significant concomitant cardiac pathology (chronic heart failure NYHA class \> 1; hypertension with a risk of cardiovascular complications \> 3; history of myocardial infarction, stroke, or transient ischemic attack; presence of other decompensated cardiovascular diseases).
* ECOG performance status \> 1.
* Presence of viral or infectious diseases (human immunodeficiency virus, chronic viral hepatitis, other infectious diseases in the acute phase).
* History of clinically significant central nervous system disorders.
* Clinically significant peripheral polyneuropathy (\> grade 2).
* Pregnancy or lactation.
* Individual intolerance to the components of the treatment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No